Nature Immunology APC and Open Access: Current Nature Portfolio Pricing and What the Fee Buys

The current Nature Immunology publishing-options page sets out the fee plainly:

• $12,850 / EUR 10,850 / GBP 9,390
• gold-OA path for primary research articles
• hybrid structure, so standard publication still exists

The current metrics page adds the live editorial and visibility signals:

• 27.6 impact factor
• 29.2 five-year impact factor
• 5 days median first editorial decision
• 180 days median acceptance
• 7,030,913 downloads in 2025

The OA funding and portfolio policy pages add the cost-modifier layer:

• some institutions can cover the APC under Nature Portfolio agreements
• lower-income-country support remains available
• the currently stated portfolio-wide support framework is described through the end of 2026

Nature Immunology is not a journal where authors choose open access first and journal fit second.

The order is the reverse:

1. survive one of the field's hardest editorial screens
2. clear peer review
3. then decide whether immediate access is worth paying for

That is why the APC question is narrower than it looks. Most manuscripts will never get far enough into the workflow for the invoice to matter.

These are the numbers of a true flagship specialty journal. The APC is expensive because the journal is still operating near the top of the immunology hierarchy.

The year-over-year move is slightly negative. Nature Immunology is down from 28.2 in 2023 to 27.6 in 2024. That still leaves it in clear flagship territory. It just means the APC should be justified by journal fit and access needs, not by vague prestige assumptions alone.

The practical planning rule is:

• start with the sticker price of $12,850
• check institutional coverage first
• then check funder support
• then check lower-income-country eligibility

That order matters because Nature Portfolio agreement coverage can collapse the out-of-pocket cost from five figures to effectively zero.

For authors paying directly, the APC is substantial enough that the access rationale should be explicit.

In our pre-submission review work, the APC is almost never the central problem.

The real bottleneck is editorial breadth. Many technically strong immunology papers still look too incremental for Nature Immunology.

Mechanistic depth is necessary but not sufficient. The journal also wants field-level consequence, not just competent experiments on a familiar axis.

The fast decision metric matters. A 5-day median first editorial decision means the journal is deciding scope quickly. That makes APC planning secondary to narrative positioning and scientific consequence.

So the decision sequence should be:

1. confirm field-level consequence
2. confirm article-type eligibility
3. then check APC coverage

Nature Immunology's current listed APC is $12,850, but the real decision is still editorial.

If the paper is genuinely competitive for the journal and immediate access matters, the fee can be justified. If not, the better move is usually to fix the targeting question before spending time on APC planning.